Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-07-25
2006-07-25
Smith, Lynette R. F. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A, C435S069100
Reexamination Certificate
active
07081529
ABSTRACT:
This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
REFERENCES:
patent: 5601823 (1997-02-01), Williams et al.
patent: 5916193 (1999-06-01), Stevens et al.
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6214602 (2001-04-01), Zdanovsky
patent: 6270777 (2001-08-01), Sokol et al.
patent: 6287566 (2001-09-01), Dertzbaugh
patent: 6461617 (2002-10-01), Shone et al.
patent: 6495143 (2002-12-01), Lee et al.
patent: 6521235 (2003-02-01), Johnston et al.
patent: 6713444 (2004-03-01), Garcia et al.
patent: 98/08540 (1998-03-01), None
patent: 9715394 (1998-05-01), None
patent: 0012890 (2000-11-01), None
Binz, T et al, Journal of biological chemistry, vol. 265(16), pp. 9153-9158, Jun. 5.
Campbell, KD et al, J. Clin. Microbiol. 1993, Sep., vol. 31(9), pagtes 2255-2262.
Campbell, K et al, Biochim Biophys ACTA, 1993, Dec. 14, vol. 1216(3), pp. 487-491.
Dasgupta, Bibhuti R et al, Biochimie, vol. 70, pp. 811-817, 1988.
East, AK et al, International Journal of Systematic Bacteriology, Voo. 46(4), pp. 1105-1112, Oct. 1996.
Evans, DM e tal, Eur. J. Biochem, vol. 154, pp. 409-416, 1986.
Fach, P et al, Applied and Environmental Microbiology, Jan. 1995, pp. 389-392, vol. 61(1).
Fujinage, Y et al, vol. 213(3), pp. 737-745, Aug. 24, 1995.
Halpern, JL et al, Journal of Biological Chemistry, vol. 268(15), May 25, 1993, pp. 11188-11192.
Hutson, RA et al, Curr. Microbiol. 1994, Voo. 28(2), pates 101-110.
Jung, HH et al, FEMS Microbiol. Lett, Feb. 1, 1992, vol. 91, pp. 69-72.
Szabo, EA et al. AppOl. Environ Microbiol. Sep. 1993, vol. 59(9), pp. 3011-3020.
Thompson, DE et al, FEMS Microbiol Lett. 1993, Apr. 1, vol. 108(2), pp. 175-182.
Thompson, De et al, Eur. J. Biochem, vol. 189, pp. 73-81, 1990.
Whelan, Sarah M. et al, applied and Environmental Microbiology, Aug. 1992, Vol. 58(8), pp. 2345-2354.
Whelan et al (reference of record), App & Environmental Microbiol, Aug. 1992, vol. 58(8), p. 2345-2356.
Smith et al (reference of record), Toxicon, vol. 36 (11) pp. 1539-1548, 1998.
Halpern et al (reference of record) May 1993, J. Biol. Chem., vol. 268(15), May 25, p. 11188-11192.
Ahmed SA et al., 2001, “Enzymatic autocatalysis of botulinum A neurotoxin light chain”J. Protein Chem.20(3):221-231.
Schmidt JJ et al., 2001, “High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F”Analytical Biochemistry296:130-137.
URL:http://www.cdc.gov
cidod/srp/drugservice/immuodrugs.htm, 2001, “Immunobiologic Agents and Drugs Available from the Centers for Disease Control. Descriptions, Recommendations, Adverse Reactions and Serologic Response” Centers for Disease Control, Atlanta, GA.
Ahmed SA et al., 2000, “Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active”J. Protein Chem.19(6):475-487.
Alderton JM et al., 2000, “Evidence for a vesicle-mediated maintenance of store-operated calcium channels in human embryoinic kidney cell line”Cell Calcium28(3):161-169.
Byrne MP et al., 2000, “Fermentation, purification, and efficacy of a recombinant vaccine candidiate against botulinum neurotoxin type F fromPichia pastoris” Protein Expr Purif.18(3):327-337.
Dalbey RE et al., 2000, “Evolutionarily related insertion pathways of bacterial, mitochondrial, and thylakoid membrane proteins”Annu. Rev. Cell Dev. Biol.16:51-87.
Ettinger RA et al., 2000, “Beta 57-Asp plays an essential role in the unique SDS stability of HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC allele associated with protection from insulin-dependent diabetes mellitus”J. Immunol165:3232-3238.
Kadkhodayan S et al., 2000, “Cloning, expression, and one-step purfication of the minimal essential domain of the light chain of botulinum neurotoxin type A”Protein Expr. Purif.19(1):125-130.
Knapp M et al., 2000, “The crystal structure of botulinum toxin A zinc protease domain.” Presented at teh 37th Annual Meeting of the Interagency Botulinum Research Coordinating Committee, Oct. 17-20, 2000, Alisomar, California.
Li L et al., 2000, “Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure”Biochemistry39:10581-10586.
Strasser A et al., 2000, “Apoptosis signaling”Annu. Rev. Biochem69:217-245.
Cai S et al., 1999, “Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol”Biochemistry38:6903-6910.
Caliborne A et al., 1999, “Protein-sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation”Biochemistry38:15407-15416.
Lacy DB et al., 2999, “Sequence homology and structural analysis of the clostridial neurotoxins”J. Mol. Biol.291:1091-1104.
Li L et al., 1999, “High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain”Protein Expr. Purif.17:339-344.
Li L et al., 1000, “In vitro translation of type A Clostridium botulinum neurotoxin heavy chain an analysis of its binding to rat synaptosomes”J Protein Chem.18(1):89-95.
Byrne MP et al., 1998, “Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain fromPichia pastorisas a Recombinant Vaccine Candidate,”Infect. Immun.66:4817-4822.
Fu F et al., 1998, “Role of zinc in the structure and toxic activity of botulinum neurotoxin”Biochemistry37:5267-5278.
Lacy DB et al., 1998, “Crystal Structure of Botulinum Neurotoxin Type A and Implications for Toxicity,”Nat. Struct. Biol.5:898-902.
Nowakowski JL et al., 1998, “Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B”J. Protein Chem.17:453-462.
Potter KJ et al., 1998, “Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeastPichia pastoris” Protein Expr Purif.13(3):357-365.
Schmidt JJ et al., 1998, “Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1′ binding subsite”FEBS Lett.435:61-64.
Smith LA, 1998, “Development of recombinant vaccines for botulinum neurotoxin”Toxicon.36(11):1539-48.
Adler M et al., 1997, “Protection by the heavy metal chelator N,N,N′, N′-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B”Toxicon35:1089-1100.
Brown DR et al., 1997, “Identification and Characterization of a Neutralizing Monoclonal Antibody Against Botulinum Neurotoxin, Serotype F, Following Vaccination with Active Toxin,”Hybridoma, 16:447-456.
Chen F et al., 1997 “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms”Infect. Immun.65:1626-1630
Chiruvolu V et al., 1997, Recombinant Protein Expression in an Alcohol Oxidase-Defective Strain ofPichia pastorisin Feed-Batch Fermentations,Enzyme Microbiol. Technol.21:277-283.
Kiyatkin N et al., 1997, “Induction of an immune response by oral administration of recombinant botulinum toxin”Infect. Immun.65:4586-4591.
Lebeda FJ et al., 1997, “Predicting Differential Antigen-Antibody Contact Regions Based on Solvent Accessibility,”J. Protein Chem.16:607-618.
Schmidt JJ et al., 1997, “Endoproteinase activity of type A
Brown Douglas R.
Byrne Michael P.
Clayton Michael A.
Lapenotiere Hugh
Middlebrook John L.
Arwine Elizabeth
Portner Ginny Allen
Smith Lynette R. F.
The United States of America as represented by the Secretary of
LandOfFree
Recombinant vaccine against botulinum neurotoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant vaccine against botulinum neurotoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant vaccine against botulinum neurotoxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586780